AUSTIN, Texas, July 31, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, will hold a conference call on Wednesday, August 14, 2013, at 4:30 p.m. Eastern time to discuss results for the second quarter ended June 30, 2013. Financial results will be issued in a press release prior to the call. Vermillion's President and CEO Thomas McLain will host the call, followed by a question and answer period. Date: Wednesday, August 14, 2013Time: 4:30 p.m. Eastern time ( 3:30 p.m. Central time)Dial-in number: 1-800-732-5617 International: 1-212-231-2906Conference ID: 21668439Webcast: http://www.media-server.com/m/p/v7m7pi5y The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860. A replay of the call will be available approximately two hours after the call through August 28, 2013. Toll-free replay number: 1-800-633-8284International replay number: 1-402-977-9140Replay ID: 21668439 About VermillionVermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology and women's health. The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and curable EOC stage, compared with 57% for the conventional biomarker CA125. In addition, OVA1 found 82% of malignancies missed by non-specialist pre-surgical assessment, and it increased detection of malignancy over ACOG guidelines from 77% to 94%. As the first protein-based, In Vitro Diagnostic Multivariate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics. Additional information about these published clinical trials is available on Vermillion's website at www.vermillion.com. Investor Relations Contact:Liolios Group, Inc. Ron Both Tel 1-949-574-3860 firstname.lastname@example.org SOURCE Vermillion, Inc.